Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

lurtotecan liposome

Known as: liposomal lurtotecan, liposome, lurtotecan 
A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVES To determine the safety and efficacy of a novel topoisomerase I inhibitor, liposomal lurtotecan, in patients with… Expand
Is this relevant?
2004
2004
The purpose of this study was to evaluate the activity and safety of OSI-211, the liposomal form of lurtotecan, in patients… Expand
Is this relevant?
2004
2004
Purpose: To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2003
2003
OSI-211 (liposomal lurtotecan), was evaluated using several different dose schedules (1mg/kg, d1-5, 1.75 mg/kg d1, 3, 5 and 6 mg… Expand
Is this relevant?
2001
2001
Prolonging tumor exposure to topoisomerase I inhibitors has been correlated to enhance the efficacy of those agents. Lurtotecan… Expand
Is this relevant?